Logo

GDTC

CytoMed Therapeutics Limited

GDTC

CytoMed Therapeutics Limited • NASDAQ
$1.84 ▼ -3.19% (-0.06)
Market Cap $21.59 M
52w High $4.05
52w Low $1.65
Dividend Yield 0%
P/E -7.36
Volume 2.55K
Outstanding Shares 11.73M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $105.705K ▲ $608.93K ▲ $-882.3K ▼ -834.681% ▲ $-0.075 ▼ $-804.323K ▼
Q1-2025 $100.043K ▲ $576.314K ▲ $-835.042K ▲ -834.683% ▲ $-0.071 ▲ $-761.242K ▼
Q4-2024 $52.415K ▼ $466.024K ▼ $-1.077M ▼ -2.055K% ▼ $-0.093 ▼ $-482.442K ▲
Q3-2024 $108.617K ▲ $495.222K ▼ $-555.676K ▲ -511.592% ▲ $-0.048 ▲ $-512.668K ▲
Q2-2024 $82.667K $1.27M $-807.96K -977.367% $-0.07 $-688.745K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $2.245M ▲ $6.572M ▲ $892.509K ▲ $5.62M ▲
Q1-2025 $2.125M ▼ $6.22M ▼ $844.704K ▲ $5.319M ▼
Q4-2024 $3.639M ▼ $7.372M ▼ $749.763K ▼ $6.565M ▼
Q3-2024 $3.867M ▼ $7.834M ▼ $796.737K ▲ $6.976M ▼
Q2-2024 $5.032M $8.046M $552.246K $7.495M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-882.3K ▼ $-1.163M ▼ $-276.442K ▼ $-18.553K ▼ $-1.202M ▼ $-765.592K ▼
Q1-2025 $-835.042K ▼ $-595.148K ▲ $-8.398K ▼ $-12.977K ▲ $0 ▲ $-724.585K ▲
Q4-2024 $-522.914K ▲ $-842.603K ▼ $1.9M ▲ $-18.968K ▼ $-979.701K ▼ $-748.388K ▲
Q3-2024 $-555.676K ▼ $-604.6K ▲ $1.173M ▲ $-13.752K ▲ $0 ▲ $-795.276K ▼
Q2-2024 $-401.344K $-865.332K $-1.401M $-14.651K $-2.396M $-761.83K

Five-Year Company Overview

Income Statement

Income Statement CytoMed is a classic early-stage biotech: no product revenue yet and recurring losses as it spends on development and overhead. Earnings per share have been negative for several years, which is normal for a company still in the clinical and preclinical phases. The key point is that the business is entirely dependent on future clinical and partnership success; current financial performance does not yet reflect commercial traction.

Balance Sheet

Balance Sheet The balance sheet is very light, with only modest assets, mostly in the form of cash and some equipment or intangibles, and no reported debt. Equity is small, which reflects the company’s young stage and limited capital base. The lack of borrowings reduces financial leverage risk, but the thin capital cushion means the company is sensitive to funding needs and market conditions when it seeks more capital.

Cash Flow

Cash Flow Reported cash flow data are minimal and not very informative, but as a pre-revenue biotech, CytoMed is almost certainly using cash rather than generating it. Operating cash outflows are likely driven by research, clinical trials, and overhead, while investment cash flows should remain modest until larger-scale facilities or trials ramp up. The business model depends on periodic external financing, grants, or partnership payments to sustain operations until any products reach the market.

Competitive Edge

Competitive Edge CytoMed sits in a crowded and fast-moving immunotherapy field but focuses on a specialized niche: off-the-shelf gamma delta T cell and iPSC-derived cell therapies. Its strengths include access to A*STAR-originated science, granted patents in major markets, an in-house GMP manufacturing facility, and a cost-conscious allogeneic approach. Offsetting this, the company is small, early in clinical development, and competing against much larger, better-funded global players in cell therapy. Its current position is that of an innovative but still unproven challenger.

Innovation and R&D

Innovation and R&D Innovation is the core of CytoMed’s story. It is developing next-generation, off-the-shelf cell therapies using gamma delta T cells and iPSC-derived immune cells, aiming for broader cancer coverage, simpler manufacturing, and better affordability than many existing CAR-T treatments. The pipeline spans a lead CAR-gamma delta T cell in early human trials, additional gamma delta programs for blood cancers, a stem-cell–based platform, and even a regenerative medicine candidate for cartilage. The recent acquisition of a clinically tested gamma delta asset with orphan drug status adds depth. The main risk is that most of this work is still at an early stage, with limited human data so far and significant scientific, regulatory, and execution hurdles ahead.

Summary

CytoMed is a very early-stage, science-driven biotech with no current revenue and ongoing losses, backed by a thin but debt-free balance sheet. Its value proposition rests on innovative off-the-shelf cell therapy platforms, protected by patents and supported by in-house manufacturing, targeting both solid and blood cancers and potentially other diseases. The opportunity lies in the novelty and potential scalability of its technologies; the risks lie in clinical uncertainty, long timelines, high development costs, and ongoing dependence on external funding and partnerships. Overall, this is a high-risk, high-uncertainty profile typical of small clinical-stage biotech firms, where future outcomes hinge on trial results and the ability to secure capital and collaborations.

NEWS

October 2, 2025 · 7:00 AM UTC

CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia

Read more